ArticleJAMA oncology2019

Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer-In Reply.

Steven D Criss et al.PubMed ↗Publisher ↗

No numbers read from the abstract.